Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma

Overview

Previous rather poor results in liver transplantation (LT) of patients with advanced hepatocellular carcinoma (HCC) have made the application of LT very limited in treatment of HCC. The advantages of ADV-TK gene therapy highlight its potentiality as adjuvant treatment for HCC patients after LT. We reported here the improved outcome of LT with combined treatment of ADV-TK gene therapy in patients with intermediate or advanced HCC.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)

Detailed Description

The overall survival in the LT with ADV-TK gene therapy group was 54.8 % at three years, and the recurrence-free survival in the same group was 56.5 %, both being higher than those in the transplantation only group (P=0.0001 for overall survival and P=0.0000 for recurrence-free survival). In no-vascular invasion subgroup treated with LT with ADV-TK therapy, both overall survival and recurrence-free survival were 100 %, significantly higher than those with vascular invasion subgroup treated with the combined LT and ADV-TK therapy (P=0 for each group). Vascular invasion was an important factor affected survival and recurrence, hazard ratio=3.687; P=0.014 and hazard ratio=12.961; P=0.000, respectively.

Interventions

  • Genetic: ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy

Clinical Trial Outcome Measures

Primary Measures

  • overall survival rate at one year
  • overall survival rate at two year
  • overall survival rate at three year
  • overall recurrence-free survival rate at one year
  • overall recurrence-free survival rate at two year
  • overall recurrence-free survival rate at three year

Secondary Measures

  • AFP level before and after liver transplantation
  • hazard rate of age on survival rate and recurrence-free survival rate
  • hazard rate of TNM stage on survival rate and recurrence-free survival rate
  • hazard rate of Child-Pugh classification on survival rate and recurrence-free survival rate
  • hazard rate of vascular invasion on survival rate and recurrence-free survival rate

Participating in This Clinical Trial

Inclusion Criteria

  • Clinical diagnosis of advanced hepatocellular carcinoma with no metastasis in lungs and bones – Accept Liver Transplantation Exclusion Criteria:

  • Small hepatocellular carcinoma – Advanced hepatocellular with metastasis in lungs and bones

Gender Eligibility: All

Minimum Age: 0 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Beijing Chao Yang Hospital
  • Collaborator
    • Tongji University
  • Overall Official(s)
    • Ding Ma, M.D., Study Chair, Cancer Biology Research Center, Tongji Hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R.China
    • Ning Li, B.D, Study Director, Beijing Chao Yang Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.